RNA Stock Hits Record High on Entering the Cardiac Disease Space

Shares of Avidity Biosciences (RNA) rose more than 12% on Wednesday after the company announced that it is expanding its current RNA-based pipeline of rare muscle disorders to explore a new therapeutic area — precision cardiology.Avidity Enters the Cardio Space With Two New DrugsThe company has decided to advance two new wholly-owned pipeline drugs, AOC 1086 and AOC 1072, targeting two rare genetic cardiomyopathies, PLN cardiomyopathy and PRKAG2 syndrome, respectively.There is currently no FDA-approved ther ...